Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Dianthus Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 54 | 1 | 52 | −1 |
| Shares | 28.1M | 441.1K | 29.7M | +1.99M (+7.2%) |
| Value | $11.1M | $174.0K | $23.6M | +$12.6M (+115.3%) |
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Dianthus Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tang Capital Management LLC | 6,050,000 | $4.81M | 0.72% |
| Lion Point Capital, LP | 4,558,466 | $3.62M | 2.00% |
| Verition Fund Management LLC | 2,198,465 | $1.75M | 0.03% |
| Western Standard LLC | 1,439,374 | $1.14M | 1.16% |
| TCW Group Inc | 750,000 | $596.0K | 0.01% |
| Susquehanna International Group, LLP | 181,503 | $144.2K | 0.00% |
| Marshall Wace, LLP | 157,670 | $124.6K | 0.00% |
| Corsair Capital Management, L.P. | 32,846 | $26.1K | 0.01% |
| Virtu Financial LLC | 10,724 | $9.00K | 0.00% |
| Sound View Wealth Advisors Group, LLC | 10,500 | $8.34K | 0.00% |
| UBS Group AG | 2,797 | $2.22K | 0.00% |
| Simplex Trading, LLC | 3,241 | $2.00K | 0.00% |
| FMR LLC | 254 | $202 | 0.00% |
Sold out (14)
Institutions that held Dianthus Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| TRV GP IV, LLC | 6,758,204 | $2.67M |
| Deep Track Capital, LP | 3,000,000 | $1.19M |
| Millennium Management LLC | 2,313,552 | $914.0K |
| Adage Capital Partners GP, L.L.C. | 868,650 | $343.1K |
| Integral Health Asset Management, LLC | 416,000 | $164.3K |
| Bleichroeder LP | 346,631 | $136.9K |
| Dimensional Fund Advisors LP | 152,984 | $60.0K |
| Thrivent Financial for Lutherans | 129,395 | $47.0K |
| Connor, Clark & Lunn Investment Management Ltd. | 75,806 | $29.9K |
| Goldman Sachs Group Inc | 38,059 | $15.0K |
| Engineers Gate Manager LP | 34,090 | $13.5K |
| Ergoteles LLC | 21,800 | $8.61K |
| StoneX Group Inc. | 12,237 | $4.83K |
| Citigroup Inc | 737 | $291 |
Not filed for Q1 2023 yet (1)
Institutions that held Dianthus Therapeutics, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Hellman Jordan Management Co Inc | 441,125 | $174.0K |